MedTrace Logo

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-02-05

Study results available
· View outcomes & findings →

Summary

This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL).

The names of the study drugs involved in this study are:

* Ipilimumab
* Nivolumab

Conditions

  • Hodgkin Lymphoma
  • Relapsed Hodgkin's Disease, Adult
  • Refractory Hodgkin Lymphoma

Interventions

DRUG

Nivolumab

Intravenous infusion

DRUG

Ipilimumab

Intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Reid W Merryman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-04
Primary Completion
2024-04-01
Completion
2026-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938232 on ClinicalTrials.gov